Journal
VIRCHOWS ARCHIV
Volume 479, Issue 1, Pages 209-214Publisher
SPRINGER
DOI: 10.1007/s00428-021-03100-x
Keywords
CD73; Immunohistochemistry; Thyroid adenoma; Thyroid carcinoma; Papillary thyroid carcinoma
Categories
Funding
- Universite de Lausanne
- European Community [602200]
Ask authors/readers for more resources
The study evaluates CD73 expression in different thyroid tumors, showing enhanced CD73 expression in papillary thyroid carcinomas compared to other types. CD73 expression patterns vary among different thyroid tumors.
CD73 converts AMP to adenosine, an immunosuppressive metabolite that promotes tumorigenesis. This study presents a systematic evaluation of CD73 expression in benign, hyperplastic, and neoplastic thyroid. CD73 expression was assessed by immunohistochemistry in 142 thyroid samples. CD73 was expressed in normal thyroid (3/6) and goiter (5/6), with an apical pattern and mild intensity. Apical and mild CD73 expression was also present in oncocytic cell adenomas/carcinomas (9/10; 5/8) and in follicular adenomas/carcinomas (12/18; 23/27). In contrast, papillary thyroid carcinomas featured extensive and intense CD73 staining (49/50) (vs. normal thyroid/goiter, p < 0.001). Seven of nine anaplastic carcinomas were CD73-positive with heterogeneous extensiveness of staining. Medullary and poorly differentiated carcinomas were mostly CD73-negative (1/6; 2/2). These results were corroborated by NT5E mRNA profiling. Papillary carcinomas feature enhanced CD73 protein and mRNA expression with distinct and intense staining, more pronounced in the invasive fronts of the tumors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available